Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.

Conclusions: 1. Cinacalcet decreases serum PTH concentration in most haemodialysed CKD patients with sHPT. 2. In 28% of patients, resistance to treatment with cinacalcet was observed. 3. Cinacalcet treatment was well tolerated and caused only a few side effects. (Endokrynol Pol 2013; 64 (2): 176-181).
PMID: 23873419 [PubMed - in process]

Source: Endokrynologia Polska - July 24, 2013 Category: Endocrinology Authors: Kuczera P, Adamczak M, Więcek A Tags: Endokrynol Pol Source Type: research